<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" version="1.1" class="marks" width="406" height="368" viewBox="0 0 406 368"><rect width="406" height="368" fill="white"/><g fill="none" stroke-miterlimit="10" transform="translate(35,5)"><g class="mark-group role-frame root" role="graphics-object" aria-roledescription="group mark container"><g transform="translate(0,0)"><path class="background" aria-hidden="true" d="M0,0h300v150h-300Z" stroke="#ddd" stroke-width="0"/><g><g class="mark-rect role-mark marks" role="graphics-object" aria-roledescription="rect mark container"><path aria-label="modePair: API_3x:API_5x; statement_key: a; pearson_r: 0.98; statements: a. Association with type I interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M0,0h20v18.75h-20Z" fill="rgb(153, 74, 7)"/><path aria-label="modePair: API_3x:API_5x; statement_key: b; pearson_r: 0.95; statements: b. Association with type II interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M0,18.75h20v18.75h-20Z" fill="rgb(184, 96, 11)"/><path aria-label="modePair: API_3x:API_5x; statement_key: c; pearson_r: 0.93; statements: c. Association with type III interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M0,37.5h20v18.75h-20Z" fill="rgb(204, 113, 19)"/><path aria-label="modePair: API_3x:API_5x; statement_key: d; pearson_r: 0.97; statements: d. Relevance to circulating leukocytes immune biology" role="graphics-symbol" aria-roledescription="rect mark" d="M0,56.25h20v18.75h-20Z" fill="rgb(163, 81, 8)"/><path aria-label="modePair: API_3x:API_5x; statement_key: e; pearson_r: 0.87; statements: e. Used as a biomarker in clinical settings" role="graphics-symbol" aria-roledescription="rect mark" d="M0,75h20v18.75h-20Z" fill="rgb(244, 174, 90)"/><path aria-label="modePair: API_3x:API_5x; statement_key: f; pearson_r: 0.84; statements: f. Potential value as a blood transcriptional biomarker" role="graphics-symbol" aria-roledescription="rect mark" d="M0,93.75h20v18.75h-20Z" fill="rgb(251, 202, 139)"/><path aria-label="modePair: API_3x:API_5x; statement_key: g; pearson_r: 0.97; statements: g. Known drug target" role="graphics-symbol" aria-roledescription="rect mark" d="M0,112.5h20v18.75h-20Z" fill="rgb(163, 81, 8)"/><path aria-label="modePair: API_3x:API_5x; statement_key: h; pearson_r: 0.97; statements: h. Therapeutically relevant for immune system diseases" role="graphics-symbol" aria-roledescription="rect mark" d="M0,131.25h20v18.75h-20Z" fill="rgb(163, 81, 8)"/><path aria-label="modePair: API_3x:Manual_US; statement_key: a; pearson_r: 0.96; statements: a. Association with type I interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M80,0h20v18.75h-20Z" fill="rgb(174, 89, 10)"/><path aria-label="modePair: API_3x:Manual_US; statement_key: b; pearson_r: 0.92; statements: b. Association with type II interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M80,18.75h20v18.75h-20Z" fill="rgb(212, 123, 28)"/><path aria-label="modePair: API_3x:Manual_US; statement_key: c; pearson_r: 0.88; statements: c. Association with type III interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M80,37.5h20v18.75h-20Z" fill="rgb(239, 164, 73)"/><path aria-label="modePair: API_3x:Manual_US; statement_key: d; pearson_r: 0.95; statements: d. Relevance to circulating leukocytes immune biology" role="graphics-symbol" aria-roledescription="rect mark" d="M80,56.25h20v18.75h-20Z" fill="rgb(184, 96, 11)"/><path aria-label="modePair: API_3x:Manual_US; statement_key: e; pearson_r: 0.73; statements: e. Used as a biomarker in clinical settings" role="graphics-symbol" aria-roledescription="rect mark" d="M80,75h20v18.75h-20Z" fill="rgb(212, 230, 239)"/><path aria-label="modePair: API_3x:Manual_US; statement_key: f; pearson_r: 0.89; statements: f. Potential value as a blood transcriptional biomarker" role="graphics-symbol" aria-roledescription="rect mark" d="M80,93.75h20v18.75h-20Z" fill="rgb(235, 153, 57)"/><path aria-label="modePair: API_3x:Manual_US; statement_key: g; pearson_r: 0.77; statements: g. Known drug target" role="graphics-symbol" aria-roledescription="rect mark" d="M80,112.5h20v18.75h-20Z" fill="rgb(242, 240, 235)"/><path aria-label="modePair: API_3x:Manual_US; statement_key: h; pearson_r: 0.95; statements: h. Therapeutically relevant for immune system diseases" role="graphics-symbol" aria-roledescription="rect mark" d="M80,131.25h20v18.75h-20Z" fill="rgb(184, 96, 11)"/><path aria-label="modePair: API_3x:Manual_Thailand; statement_key: a; pearson_r: 0.95; statements: a. Association with type I interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M60,0h20v18.75h-20Z" fill="rgb(184, 96, 11)"/><path aria-label="modePair: API_3x:Manual_Thailand; statement_key: b; pearson_r: 0.89; statements: b. Association with type II interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M60,18.75h20v18.75h-20Z" fill="rgb(235, 153, 57)"/><path aria-label="modePair: API_3x:Manual_Thailand; statement_key: c; pearson_r: 0.83; statements: c. Association with type III interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M60,37.5h20v18.75h-20Z" fill="rgb(252, 210, 156)"/><path aria-label="modePair: API_3x:Manual_Thailand; statement_key: d; pearson_r: 0.89; statements: d. Relevance to circulating leukocytes immune biology" role="graphics-symbol" aria-roledescription="rect mark" d="M60,56.25h20v18.75h-20Z" fill="rgb(235, 153, 57)"/><path aria-label="modePair: API_3x:Manual_Thailand; statement_key: e; pearson_r: 0.57; statements: e. Used as a biomarker in clinical settings" role="graphics-symbol" aria-roledescription="rect mark" d="M60,75h20v18.75h-20Z" fill="rgb(26, 86, 144)"/><path aria-label="modePair: API_3x:Manual_Thailand; statement_key: f; pearson_r: 0.78; statements: f. Potential value as a blood transcriptional biomarker" role="graphics-symbol" aria-roledescription="rect mark" d="M60,93.75h20v18.75h-20Z" fill="rgb(244, 236, 223)"/><path aria-label="modePair: API_3x:Manual_Thailand; statement_key: g; pearson_r: 0.73; statements: g. Known drug target" role="graphics-symbol" aria-roledescription="rect mark" d="M60,112.5h20v18.75h-20Z" fill="rgb(212, 230, 239)"/><path aria-label="modePair: API_3x:Manual_Thailand; statement_key: h; pearson_r: 0.9; statements: h. Therapeutically relevant for immune system diseases" role="graphics-symbol" aria-roledescription="rect mark" d="M60,131.25h20v18.75h-20Z" fill="rgb(229, 143, 44)"/><path aria-label="modePair: API_3x:Manual_Qatar; statement_key: a; pearson_r: 0.97; statements: a. Association with type I interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M40,0h20v18.75h-20Z" fill="rgb(163, 81, 8)"/><path aria-label="modePair: API_3x:Manual_Qatar; statement_key: b; pearson_r: 0.93; statements: b. Association with type II interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M40,18.75h20v18.75h-20Z" fill="rgb(204, 113, 19)"/><path aria-label="modePair: API_3x:Manual_Qatar; statement_key: c; pearson_r: 0.84; statements: c. Association with type III interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M40,37.5h20v18.75h-20Z" fill="rgb(251, 202, 139)"/><path aria-label="modePair: API_3x:Manual_Qatar; statement_key: d; pearson_r: 0.92; statements: d. Relevance to circulating leukocytes immune biology" role="graphics-symbol" aria-roledescription="rect mark" d="M40,56.25h20v18.75h-20Z" fill="rgb(212, 123, 28)"/><path aria-label="modePair: API_3x:Manual_Qatar; statement_key: e; pearson_r: 0.81; statements: e. Used as a biomarker in clinical settings" role="graphics-symbol" aria-roledescription="rect mark" d="M40,75h20v18.75h-20Z" fill="rgb(252, 225, 188)"/><path aria-label="modePair: API_3x:Manual_Qatar; statement_key: f; pearson_r: 0.85; statements: f. Potential value as a blood transcriptional biomarker" role="graphics-symbol" aria-roledescription="rect mark" d="M40,93.75h20v18.75h-20Z" fill="rgb(251, 194, 123)"/><path aria-label="modePair: API_3x:Manual_Qatar; statement_key: g; pearson_r: 0.79; statements: g. Known drug target" role="graphics-symbol" aria-roledescription="rect mark" d="M40,112.5h20v18.75h-20Z" fill="rgb(247, 232, 212)"/><path aria-label="modePair: API_3x:Manual_Qatar; statement_key: h; pearson_r: 0.94; statements: h. Therapeutically relevant for immune system diseases" role="graphics-symbol" aria-roledescription="rect mark" d="M40,131.25h20v18.75h-20Z" fill="rgb(195, 104, 13)"/><path aria-label="modePair: API_3x:Claude-3; statement_key: a; pearson_r: 0.9; statements: a. Association with type I interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M20,0h20v18.75h-20Z" fill="rgb(229, 143, 44)"/><path aria-label="modePair: API_3x:Claude-3; statement_key: b; pearson_r: 0.79; statements: b. Association with type II interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M20,18.75h20v18.75h-20Z" fill="rgb(247, 232, 212)"/><path aria-label="modePair: API_3x:Claude-3; statement_key: c; pearson_r: 0.85; statements: c. Association with type III interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M20,37.5h20v18.75h-20Z" fill="rgb(251, 194, 123)"/><path aria-label="modePair: API_3x:Claude-3; statement_key: d; pearson_r: 0.9; statements: d. Relevance to circulating leukocytes immune biology" role="graphics-symbol" aria-roledescription="rect mark" d="M20,56.25h20v18.75h-20Z" fill="rgb(229, 143, 44)"/><path aria-label="modePair: API_3x:Claude-3; statement_key: e; pearson_r: 0.6; statements: e. Used as a biomarker in clinical settings" role="graphics-symbol" aria-roledescription="rect mark" d="M20,75h20v18.75h-20Z" fill="rgb(46, 118, 177)"/><path aria-label="modePair: API_3x:Claude-3; statement_key: f; pearson_r: 0.84; statements: f. Potential value as a blood transcriptional biomarker" role="graphics-symbol" aria-roledescription="rect mark" d="M20,93.75h20v18.75h-20Z" fill="rgb(251, 202, 139)"/><path aria-label="modePair: API_3x:Claude-3; statement_key: g; pearson_r: 0.68; statements: g. Known drug target" role="graphics-symbol" aria-roledescription="rect mark" d="M20,112.5h20v18.75h-20Z" fill="rgb(148, 196, 222)"/><path aria-label="modePair: API_3x:Claude-3; statement_key: h; pearson_r: 0.93; statements: h. Therapeutically relevant for immune system diseases" role="graphics-symbol" aria-roledescription="rect mark" d="M20,131.25h20v18.75h-20Z" fill="rgb(204, 113, 19)"/><path aria-label="modePair: API_5x:Manual_US; statement_key: a; pearson_r: 0.95; statements: a. Association with type I interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M160,0h20v18.75h-20Z" fill="rgb(184, 96, 11)"/><path aria-label="modePair: API_5x:Manual_US; statement_key: b; pearson_r: 0.95; statements: b. Association with type II interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M160,18.75h20v18.75h-20Z" fill="rgb(184, 96, 11)"/><path aria-label="modePair: API_5x:Manual_US; statement_key: c; pearson_r: 0.93; statements: c. Association with type III interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M160,37.5h20v18.75h-20Z" fill="rgb(204, 113, 19)"/><path aria-label="modePair: API_5x:Manual_US; statement_key: d; pearson_r: 0.98; statements: d. Relevance to circulating leukocytes immune biology" role="graphics-symbol" aria-roledescription="rect mark" d="M160,56.25h20v18.75h-20Z" fill="rgb(153, 74, 7)"/><path aria-label="modePair: API_5x:Manual_US; statement_key: e; pearson_r: 0.88; statements: e. Used as a biomarker in clinical settings" role="graphics-symbol" aria-roledescription="rect mark" d="M160,75h20v18.75h-20Z" fill="rgb(239, 164, 73)"/><path aria-label="modePair: API_5x:Manual_US; statement_key: f; pearson_r: 0.93; statements: f. Potential value as a blood transcriptional biomarker" role="graphics-symbol" aria-roledescription="rect mark" d="M160,93.75h20v18.75h-20Z" fill="rgb(204, 113, 19)"/><path aria-label="modePair: API_5x:Manual_US; statement_key: g; pearson_r: 0.78; statements: g. Known drug target" role="graphics-symbol" aria-roledescription="rect mark" d="M160,112.5h20v18.75h-20Z" fill="rgb(244, 236, 223)"/><path aria-label="modePair: API_5x:Manual_US; statement_key: h; pearson_r: 0.96; statements: h. Therapeutically relevant for immune system diseases" role="graphics-symbol" aria-roledescription="rect mark" d="M160,131.25h20v18.75h-20Z" fill="rgb(174, 89, 10)"/><path aria-label="modePair: API_5x:Manual_Thailand; statement_key: a; pearson_r: 0.95; statements: a. Association with type I interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M140,0h20v18.75h-20Z" fill="rgb(184, 96, 11)"/><path aria-label="modePair: API_5x:Manual_Thailand; statement_key: b; pearson_r: 0.89; statements: b. Association with type II interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M140,18.75h20v18.75h-20Z" fill="rgb(235, 153, 57)"/><path aria-label="modePair: API_5x:Manual_Thailand; statement_key: c; pearson_r: 0.88; statements: c. Association with type III interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M140,37.5h20v18.75h-20Z" fill="rgb(239, 164, 73)"/><path aria-label="modePair: API_5x:Manual_Thailand; statement_key: d; pearson_r: 0.85; statements: d. Relevance to circulating leukocytes immune biology" role="graphics-symbol" aria-roledescription="rect mark" d="M140,56.25h20v18.75h-20Z" fill="rgb(251, 194, 123)"/><path aria-label="modePair: API_5x:Manual_Thailand; statement_key: e; pearson_r: 0.56; statements: e. Used as a biomarker in clinical settings" role="graphics-symbol" aria-roledescription="rect mark" d="M140,75h20v18.75h-20Z" fill="rgb(19, 75, 133)"/><path aria-label="modePair: API_5x:Manual_Thailand; statement_key: f; pearson_r: 0.81; statements: f. Potential value as a blood transcriptional biomarker" role="graphics-symbol" aria-roledescription="rect mark" d="M140,93.75h20v18.75h-20Z" fill="rgb(252, 225, 188)"/><path aria-label="modePair: API_5x:Manual_Thailand; statement_key: g; pearson_r: 0.73; statements: g. Known drug target" role="graphics-symbol" aria-roledescription="rect mark" d="M140,112.5h20v18.75h-20Z" fill="rgb(212, 230, 239)"/><path aria-label="modePair: API_5x:Manual_Thailand; statement_key: h; pearson_r: 0.88; statements: h. Therapeutically relevant for immune system diseases" role="graphics-symbol" aria-roledescription="rect mark" d="M140,131.25h20v18.75h-20Z" fill="rgb(239, 164, 73)"/><path aria-label="modePair: API_5x:Manual_Qatar; statement_key: a; pearson_r: 0.96; statements: a. Association with type I interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M120,0h20v18.75h-20Z" fill="rgb(174, 89, 10)"/><path aria-label="modePair: API_5x:Manual_Qatar; statement_key: b; pearson_r: 0.93; statements: b. Association with type II interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M120,18.75h20v18.75h-20Z" fill="rgb(204, 113, 19)"/><path aria-label="modePair: API_5x:Manual_Qatar; statement_key: c; pearson_r: 0.9; statements: c. Association with type III interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M120,37.5h20v18.75h-20Z" fill="rgb(229, 143, 44)"/><path aria-label="modePair: API_5x:Manual_Qatar; statement_key: d; pearson_r: 0.92; statements: d. Relevance to circulating leukocytes immune biology" role="graphics-symbol" aria-roledescription="rect mark" d="M120,56.25h20v18.75h-20Z" fill="rgb(212, 123, 28)"/><path aria-label="modePair: API_5x:Manual_Qatar; statement_key: e; pearson_r: 0.92; statements: e. Used as a biomarker in clinical settings" role="graphics-symbol" aria-roledescription="rect mark" d="M120,75h20v18.75h-20Z" fill="rgb(212, 123, 28)"/><path aria-label="modePair: API_5x:Manual_Qatar; statement_key: f; pearson_r: 0.92; statements: f. Potential value as a blood transcriptional biomarker" role="graphics-symbol" aria-roledescription="rect mark" d="M120,93.75h20v18.75h-20Z" fill="rgb(212, 123, 28)"/><path aria-label="modePair: API_5x:Manual_Qatar; statement_key: g; pearson_r: 0.78; statements: g. Known drug target" role="graphics-symbol" aria-roledescription="rect mark" d="M120,112.5h20v18.75h-20Z" fill="rgb(244, 236, 223)"/><path aria-label="modePair: API_5x:Manual_Qatar; statement_key: h; pearson_r: 0.97; statements: h. Therapeutically relevant for immune system diseases" role="graphics-symbol" aria-roledescription="rect mark" d="M120,131.25h20v18.75h-20Z" fill="rgb(163, 81, 8)"/><path aria-label="modePair: API_5x:Claude-3; statement_key: a; pearson_r: 0.89; statements: a. Association with type I interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M100,0h20v18.75h-20Z" fill="rgb(235, 153, 57)"/><path aria-label="modePair: API_5x:Claude-3; statement_key: b; pearson_r: 0.77; statements: b. Association with type II interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M100,18.75h20v18.75h-20Z" fill="rgb(242, 240, 235)"/><path aria-label="modePair: API_5x:Claude-3; statement_key: c; pearson_r: 0.88; statements: c. Association with type III interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M100,37.5h20v18.75h-20Z" fill="rgb(239, 164, 73)"/><path aria-label="modePair: API_5x:Claude-3; statement_key: d; pearson_r: 0.94; statements: d. Relevance to circulating leukocytes immune biology" role="graphics-symbol" aria-roledescription="rect mark" d="M100,56.25h20v18.75h-20Z" fill="rgb(195, 104, 13)"/><path aria-label="modePair: API_5x:Claude-3; statement_key: e; pearson_r: 0.64; statements: e. Used as a biomarker in clinical settings" role="graphics-symbol" aria-roledescription="rect mark" d="M100,75h20v18.75h-20Z" fill="rgb(89, 158, 201)"/><path aria-label="modePair: API_5x:Claude-3; statement_key: f; pearson_r: 0.88; statements: f. Potential value as a blood transcriptional biomarker" role="graphics-symbol" aria-roledescription="rect mark" d="M100,93.75h20v18.75h-20Z" fill="rgb(239, 164, 73)"/><path aria-label="modePair: API_5x:Claude-3; statement_key: g; pearson_r: 0.7; statements: g. Known drug target" role="graphics-symbol" aria-roledescription="rect mark" d="M100,112.5h20v18.75h-20Z" fill="rgb(175, 211, 230)"/><path aria-label="modePair: API_5x:Claude-3; statement_key: h; pearson_r: 0.92; statements: h. Therapeutically relevant for immune system diseases" role="graphics-symbol" aria-roledescription="rect mark" d="M100,131.25h20v18.75h-20Z" fill="rgb(212, 123, 28)"/><path aria-label="modePair: Manual_US:Manual_Thailand; statement_key: a; pearson_r: 0.97; statements: a. Association with type I interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M280,0h20v18.75h-20Z" fill="rgb(163, 81, 8)"/><path aria-label="modePair: Manual_US:Manual_Thailand; statement_key: b; pearson_r: 0.94; statements: b. Association with type II interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M280,18.75h20v18.75h-20Z" fill="rgb(195, 104, 13)"/><path aria-label="modePair: Manual_US:Manual_Thailand; statement_key: c; pearson_r: 0.98; statements: c. Association with type III interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M280,37.5h20v18.75h-20Z" fill="rgb(153, 74, 7)"/><path aria-label="modePair: Manual_US:Manual_Thailand; statement_key: d; pearson_r: 0.89; statements: d. Relevance to circulating leukocytes immune biology" role="graphics-symbol" aria-roledescription="rect mark" d="M280,56.25h20v18.75h-20Z" fill="rgb(235, 153, 57)"/><path aria-label="modePair: Manual_US:Manual_Thailand; statement_key: e; pearson_r: 0.71; statements: e. Used as a biomarker in clinical settings" role="graphics-symbol" aria-roledescription="rect mark" d="M280,75h20v18.75h-20Z" fill="rgb(187, 217, 233)"/><path aria-label="modePair: Manual_US:Manual_Thailand; statement_key: f; pearson_r: 0.93; statements: f. Potential value as a blood transcriptional biomarker" role="graphics-symbol" aria-roledescription="rect mark" d="M280,93.75h20v18.75h-20Z" fill="rgb(204, 113, 19)"/><path aria-label="modePair: Manual_US:Manual_Thailand; statement_key: g; pearson_r: 0.87; statements: g. Known drug target" role="graphics-symbol" aria-roledescription="rect mark" d="M280,112.5h20v18.75h-20Z" fill="rgb(244, 174, 90)"/><path aria-label="modePair: Manual_US:Manual_Thailand; statement_key: h; pearson_r: 0.94; statements: h. Therapeutically relevant for immune system diseases" role="graphics-symbol" aria-roledescription="rect mark" d="M280,131.25h20v18.75h-20Z" fill="rgb(195, 104, 13)"/><path aria-label="modePair: Manual_US:Manual_Qatar; statement_key: a; pearson_r: 0.98; statements: a. Association with type I interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M260,0h20v18.75h-20Z" fill="rgb(153, 74, 7)"/><path aria-label="modePair: Manual_US:Manual_Qatar; statement_key: b; pearson_r: 0.96; statements: b. Association with type II interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M260,18.75h20v18.75h-20Z" fill="rgb(174, 89, 10)"/><path aria-label="modePair: Manual_US:Manual_Qatar; statement_key: c; pearson_r: 0.91; statements: c. Association with type III interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M260,37.5h20v18.75h-20Z" fill="rgb(220, 133, 36)"/><path aria-label="modePair: Manual_US:Manual_Qatar; statement_key: d; pearson_r: 0.94; statements: d. Relevance to circulating leukocytes immune biology" role="graphics-symbol" aria-roledescription="rect mark" d="M260,56.25h20v18.75h-20Z" fill="rgb(195, 104, 13)"/><path aria-label="modePair: Manual_US:Manual_Qatar; statement_key: e; pearson_r: 0.83; statements: e. Used as a biomarker in clinical settings" role="graphics-symbol" aria-roledescription="rect mark" d="M260,75h20v18.75h-20Z" fill="rgb(252, 210, 156)"/><path aria-label="modePair: Manual_US:Manual_Qatar; statement_key: f; pearson_r: 0.93; statements: f. Potential value as a blood transcriptional biomarker" role="graphics-symbol" aria-roledescription="rect mark" d="M260,93.75h20v18.75h-20Z" fill="rgb(204, 113, 19)"/><path aria-label="modePair: Manual_US:Manual_Qatar; statement_key: g; pearson_r: 0.9; statements: g. Known drug target" role="graphics-symbol" aria-roledescription="rect mark" d="M260,112.5h20v18.75h-20Z" fill="rgb(229, 143, 44)"/><path aria-label="modePair: Manual_US:Manual_Qatar; statement_key: h; pearson_r: 0.96; statements: h. Therapeutically relevant for immune system diseases" role="graphics-symbol" aria-roledescription="rect mark" d="M260,131.25h20v18.75h-20Z" fill="rgb(174, 89, 10)"/><path aria-label="modePair: Manual_US:Claude-3; statement_key: a; pearson_r: 0.84; statements: a. Association with type I interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M240,0h20v18.75h-20Z" fill="rgb(251, 202, 139)"/><path aria-label="modePair: Manual_US:Claude-3; statement_key: b; pearson_r: 0.79; statements: b. Association with type II interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M240,18.75h20v18.75h-20Z" fill="rgb(247, 232, 212)"/><path aria-label="modePair: Manual_US:Claude-3; statement_key: c; pearson_r: 0.84; statements: c. Association with type III interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M240,37.5h20v18.75h-20Z" fill="rgb(251, 202, 139)"/><path aria-label="modePair: Manual_US:Claude-3; statement_key: d; pearson_r: 0.96; statements: d. Relevance to circulating leukocytes immune biology" role="graphics-symbol" aria-roledescription="rect mark" d="M240,56.25h20v18.75h-20Z" fill="rgb(174, 89, 10)"/><path aria-label="modePair: Manual_US:Claude-3; statement_key: e; pearson_r: 0.75; statements: e. Used as a biomarker in clinical settings" role="graphics-symbol" aria-roledescription="rect mark" d="M240,75h20v18.75h-20Z" fill="rgb(227, 235, 237)"/><path aria-label="modePair: Manual_US:Claude-3; statement_key: f; pearson_r: 0.95; statements: f. Potential value as a blood transcriptional biomarker" role="graphics-symbol" aria-roledescription="rect mark" d="M240,93.75h20v18.75h-20Z" fill="rgb(184, 96, 11)"/><path aria-label="modePair: Manual_US:Claude-3; statement_key: g; pearson_r: 0.84; statements: g. Known drug target" role="graphics-symbol" aria-roledescription="rect mark" d="M240,112.5h20v18.75h-20Z" fill="rgb(251, 202, 139)"/><path aria-label="modePair: Manual_US:Claude-3; statement_key: h; pearson_r: 0.96; statements: h. Therapeutically relevant for immune system diseases" role="graphics-symbol" aria-roledescription="rect mark" d="M240,131.25h20v18.75h-20Z" fill="rgb(174, 89, 10)"/><path aria-label="modePair: Manual_Thailand:Manual_Qatar; statement_key: a; pearson_r: 0.95; statements: a. Association with type I interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M220,0h20v18.75h-20Z" fill="rgb(184, 96, 11)"/><path aria-label="modePair: Manual_Thailand:Manual_Qatar; statement_key: b; pearson_r: 0.93; statements: b. Association with type II interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M220,18.75h20v18.75h-20Z" fill="rgb(204, 113, 19)"/><path aria-label="modePair: Manual_Thailand:Manual_Qatar; statement_key: c; pearson_r: 0.91; statements: c. Association with type III interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M220,37.5h20v18.75h-20Z" fill="rgb(220, 133, 36)"/><path aria-label="modePair: Manual_Thailand:Manual_Qatar; statement_key: d; pearson_r: 0.91; statements: d. Relevance to circulating leukocytes immune biology" role="graphics-symbol" aria-roledescription="rect mark" d="M220,56.25h20v18.75h-20Z" fill="rgb(220, 133, 36)"/><path aria-label="modePair: Manual_Thailand:Manual_Qatar; statement_key: e; pearson_r: 0.61; statements: e. Used as a biomarker in clinical settings" role="graphics-symbol" aria-roledescription="rect mark" d="M220,75h20v18.75h-20Z" fill="rgb(56, 128, 184)"/><path aria-label="modePair: Manual_Thailand:Manual_Qatar; statement_key: f; pearson_r: 0.88; statements: f. Potential value as a blood transcriptional biomarker" role="graphics-symbol" aria-roledescription="rect mark" d="M220,93.75h20v18.75h-20Z" fill="rgb(239, 164, 73)"/><path aria-label="modePair: Manual_Thailand:Manual_Qatar; statement_key: g; pearson_r: 0.86; statements: g. Known drug target" role="graphics-symbol" aria-roledescription="rect mark" d="M220,112.5h20v18.75h-20Z" fill="rgb(248, 185, 106)"/><path aria-label="modePair: Manual_Thailand:Manual_Qatar; statement_key: h; pearson_r: 0.88; statements: h. Therapeutically relevant for immune system diseases" role="graphics-symbol" aria-roledescription="rect mark" d="M220,131.25h20v18.75h-20Z" fill="rgb(239, 164, 73)"/><path aria-label="modePair: Manual_Thailand:Claude-3; statement_key: a; pearson_r: 0.86; statements: a. Association with type I interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M200,0h20v18.75h-20Z" fill="rgb(248, 185, 106)"/><path aria-label="modePair: Manual_Thailand:Claude-3; statement_key: b; pearson_r: 0.89; statements: b. Association with type II interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M200,18.75h20v18.75h-20Z" fill="rgb(235, 153, 57)"/><path aria-label="modePair: Manual_Thailand:Claude-3; statement_key: c; pearson_r: 0.83; statements: c. Association with type III interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M200,37.5h20v18.75h-20Z" fill="rgb(252, 210, 156)"/><path aria-label="modePair: Manual_Thailand:Claude-3; statement_key: d; pearson_r: 0.88; statements: d. Relevance to circulating leukocytes immune biology" role="graphics-symbol" aria-roledescription="rect mark" d="M200,56.25h20v18.75h-20Z" fill="rgb(239, 164, 73)"/><path aria-label="modePair: Manual_Thailand:Claude-3; statement_key: e; pearson_r: 0.74; statements: e. Used as a biomarker in clinical settings" role="graphics-symbol" aria-roledescription="rect mark" d="M200,75h20v18.75h-20Z" fill="rgb(219, 232, 238)"/><path aria-label="modePair: Manual_Thailand:Claude-3; statement_key: f; pearson_r: 0.94; statements: f. Potential value as a blood transcriptional biomarker" role="graphics-symbol" aria-roledescription="rect mark" d="M200,93.75h20v18.75h-20Z" fill="rgb(195, 104, 13)"/><path aria-label="modePair: Manual_Thailand:Claude-3; statement_key: g; pearson_r: 0.77; statements: g. Known drug target" role="graphics-symbol" aria-roledescription="rect mark" d="M200,112.5h20v18.75h-20Z" fill="rgb(242, 240, 235)"/><path aria-label="modePair: Manual_Thailand:Claude-3; statement_key: h; pearson_r: 0.92; statements: h. Therapeutically relevant for immune system diseases" role="graphics-symbol" aria-roledescription="rect mark" d="M200,131.25h20v18.75h-20Z" fill="rgb(212, 123, 28)"/><path aria-label="modePair: Manual_Qatar:Claude-3; statement_key: a; pearson_r: 0.82; statements: a. Association with type I interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M180,0h20v18.75h-20Z" fill="rgb(252, 218, 173)"/><path aria-label="modePair: Manual_Qatar:Claude-3; statement_key: b; pearson_r: 0.76; statements: b. Association with type II interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M180,18.75h20v18.75h-20Z" fill="rgb(234, 237, 236)"/><path aria-label="modePair: Manual_Qatar:Claude-3; statement_key: c; pearson_r: 0.83; statements: c. Association with type III interferon responses" role="graphics-symbol" aria-roledescription="rect mark" d="M180,37.5h20v18.75h-20Z" fill="rgb(252, 210, 156)"/><path aria-label="modePair: Manual_Qatar:Claude-3; statement_key: d; pearson_r: 0.9; statements: d. Relevance to circulating leukocytes immune biology" role="graphics-symbol" aria-roledescription="rect mark" d="M180,56.25h20v18.75h-20Z" fill="rgb(229, 143, 44)"/><path aria-label="modePair: Manual_Qatar:Claude-3; statement_key: e; pearson_r: 0.68; statements: e. Used as a biomarker in clinical settings" role="graphics-symbol" aria-roledescription="rect mark" d="M180,75h20v18.75h-20Z" fill="rgb(148, 196, 222)"/><path aria-label="modePair: Manual_Qatar:Claude-3; statement_key: f; pearson_r: 0.9; statements: f. Potential value as a blood transcriptional biomarker" role="graphics-symbol" aria-roledescription="rect mark" d="M180,93.75h20v18.75h-20Z" fill="rgb(229, 143, 44)"/><path aria-label="modePair: Manual_Qatar:Claude-3; statement_key: g; pearson_r: 0.73; statements: g. Known drug target" role="graphics-symbol" aria-roledescription="rect mark" d="M180,112.5h20v18.75h-20Z" fill="rgb(212, 230, 239)"/><path aria-label="modePair: Manual_Qatar:Claude-3; statement_key: h; pearson_r: 0.94; statements: h. Therapeutically relevant for immune system diseases" role="graphics-symbol" aria-roledescription="rect mark" d="M180,131.25h20v18.75h-20Z" fill="rgb(195, 104, 13)"/></g><g class="mark-group role-legend" role="graphics-symbol" aria-roledescription="legend" aria-label="Gradient legend titled 'Pearson Correlation' for fill color with values from 0.6 to 1.0"><g transform="translate(318,0)"><path class="background" aria-hidden="true" d="M0,0h48v150h-48Z" pointer-events="none"/><g><g class="mark-group role-legend-entry"><g transform="translate(0,0)"><path class="background" aria-hidden="true" d="M0,0h0v0h0Z" pointer-events="none"/><g><g class="mark-rect role-legend-gradient" pointer-events="none"><path d="M0,0h16v150h-16Z" fill="url(#gradient_1)" stroke="#ddd" stroke-width="0" opacity="1"/></g><g class="mark-text role-legend-label" pointer-events="none"><text text-anchor="start" transform="translate(18,148)" font-family="sans-serif" font-size="10px" fill="#000" opacity="1">0.6</text><text text-anchor="start" transform="translate(18,8)" font-family="sans-serif" font-size="10px" fill="#000" opacity="1">1.0</text></g></g><path class="foreground" aria-hidden="true" d="" pointer-events="none" display="none"/></g></g><g class="mark-text role-legend-title" pointer-events="none"><text text-anchor="middle" transform="translate(37,75) rotate(90) translate(0,-2)" font-family="sans-serif" font-size="11px" font-weight="bold" fill="#000" opacity="1">Pearson Correlation</text></g></g><path class="foreground" aria-hidden="true" d="" pointer-events="none" display="none"/></g></g><g class="mark-group role-axis" role="graphics-symbol" aria-roledescription="axis" aria-label="X-axis for a discrete scale with 15 values: API_3x:API_5x, API_3x:Claude-3, API_3x:Manual_Qatar, API_3x:Manual_Thailand, API_3x:Manual_US, ending with Manual_US:Manual_Thailand"><g transform="translate(0.5,150.5)"><path class="background" aria-hidden="true" d="M0,0h0v0h0Z" pointer-events="none"/><g><g class="mark-rule role-axis-tick" pointer-events="none"><line transform="translate(10,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(30,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(50,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(70,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(90,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(110,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(130,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(150,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(170,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(190,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(210,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(230,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(250,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(270,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(290,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/></g><g class="mark-text role-axis-label" pointer-events="none"><text text-anchor="end" transform="translate(9.5,7) rotate(270) translate(0,4)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">API_3x:API_5x</text><text text-anchor="end" transform="translate(29.5,7) rotate(270) translate(0,4)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">API_3x:Claude-3</text><text text-anchor="end" transform="translate(49.5,7) rotate(270) translate(0,4)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">API_3x:Manual_Qatar</text><text text-anchor="end" transform="translate(69.5,7) rotate(270) translate(0,4)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">API_3x:Manual_Thailand</text><text text-anchor="end" transform="translate(89.5,7) rotate(270) translate(0,4)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">API_3x:Manual_US</text><text text-anchor="end" transform="translate(109.5,7) rotate(270) translate(0,4)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">API_5x:Claude-3</text><text text-anchor="end" transform="translate(129.5,7) rotate(270) translate(0,4)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">API_5x:Manual_Qatar</text><text text-anchor="end" transform="translate(149.5,7) rotate(270) translate(0,4)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">API_5x:Manual_Thailand</text><text text-anchor="end" transform="translate(169.5,7) rotate(270) translate(0,4)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">API_5x:Manual_US</text><text text-anchor="end" transform="translate(189.5,7) rotate(270) translate(0,4)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">Manual_Qatar:Claude-3</text><text text-anchor="end" transform="translate(209.5,7) rotate(270) translate(0,4)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">Manual_Thailand:Claude-3</text><text text-anchor="end" transform="translate(229.5,7) rotate(270) translate(0,4)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">Manual_Thailand:Manual_Qatar</text><text text-anchor="end" transform="translate(249.5,7) rotate(270) translate(0,4)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">Manual_US:Claude-3</text><text text-anchor="end" transform="translate(269.5,7) rotate(270) translate(0,4)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">Manual_US:Manual_Qatar</text><text text-anchor="end" transform="translate(289.5,7) rotate(270) translate(0,4)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">Manual_US:Manual_Thailand</text></g></g><path class="foreground" aria-hidden="true" d="" pointer-events="none" display="none"/></g></g><g class="mark-group role-axis" role="graphics-symbol" aria-roledescription="axis" aria-label="Y-axis titled 'Statement Key' for a discrete scale with 8 values: a, b, c, d, e, ending with h"><g transform="translate(0.5,0.5)"><path class="background" aria-hidden="true" d="M0,0h0v0h0Z" pointer-events="none"/><g><g class="mark-rule role-axis-tick" pointer-events="none"><line transform="translate(0,9)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,28)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,46)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,65)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,84)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,103)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,121)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,140)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/></g><g class="mark-text role-axis-label" pointer-events="none"><text text-anchor="end" transform="translate(-7,12.875)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">a</text><text text-anchor="end" transform="translate(-7,31.625)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">b</text><text text-anchor="end" transform="translate(-7,50.375)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">c</text><text text-anchor="end" transform="translate(-7,69.125)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">d</text><text text-anchor="end" transform="translate(-7,87.875)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">e</text><text text-anchor="end" transform="translate(-7,106.625)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">f</text><text text-anchor="end" transform="translate(-7,125.375)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">g</text><text text-anchor="end" transform="translate(-7,144.125)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">h</text></g><g class="mark-text role-axis-title" pointer-events="none"><text text-anchor="middle" transform="translate(-18.7861328125,75) rotate(-90) translate(0,-2)" font-family="sans-serif" font-size="11px" font-weight="bold" fill="#000" opacity="1">Statement Key</text></g></g><path class="foreground" aria-hidden="true" d="" pointer-events="none" display="none"/></g></g></g><path class="foreground" aria-hidden="true" d="" display="none"/></g></g></g><defs><linearGradient id="gradient_1" x1="0" x2="0" y1="1" y2="0"><stop offset="0" stop-color="rgb(19, 75, 133)"/><stop offset="0.04761904761904741" stop-color="rgb(32, 96, 155)"/><stop offset="0.09523809523809508" stop-color="rgb(46, 118, 177)"/><stop offset="0.14285714285714274" stop-color="rgb(67, 138, 189)"/><stop offset="0.1904761904761904" stop-color="rgb(89, 158, 201)"/><stop offset="0.23809523809523808" stop-color="rgb(117, 177, 211)"/><stop offset="0.28571428571428575" stop-color="rgb(148, 196, 222)"/><stop offset="0.33333333333333315" stop-color="rgb(175, 211, 230)"/><stop offset="0.3809523809523808" stop-color="rgb(200, 224, 236)"/><stop offset="0.4285714285714285" stop-color="rgb(219, 232, 238)"/><stop offset="0.47619047619047616" stop-color="rgb(234, 237, 236)"/><stop offset="0.5238095238095238" stop-color="rgb(244, 236, 223)"/><stop offset="0.5714285714285715" stop-color="rgb(249, 229, 200)"/><stop offset="0.619047619047619" stop-color="rgb(252, 218, 173)"/><stop offset="0.6666666666666666" stop-color="rgb(251, 202, 139)"/><stop offset="0.7142857142857143" stop-color="rgb(248, 185, 106)"/><stop offset="0.7619047619047619" stop-color="rgb(239, 164, 73)"/><stop offset="0.8095238095238095" stop-color="rgb(229, 143, 44)"/><stop offset="0.8571428571428572" stop-color="rgb(212, 123, 28)"/><stop offset="0.9047619047619047" stop-color="rgb(195, 104, 13)"/><stop offset="0.9523809523809523" stop-color="rgb(174, 89, 10)"/><stop offset="1" stop-color="rgb(153, 74, 7)"/></linearGradient></defs></svg>